(62 days)
Not Found
Abbott Test Pack Plus™,Quick-Vue®
No
The device description and performance studies describe a standard lateral flow immunoassay, which does not involve AI or ML. There are no mentions of AI, ML, or image processing.
No
This device is a diagnostic test for early pregnancy detection, not a device used for therapy or treatment.
Yes
The "Intended Use / Indications for Use" states that the device is for "the early detection of pregnancy," and the "Device Description" states it is for "the qualitative determination of human chorionic gonadotropin (hCG) in urine or in urine and serum." Both of these indicate it performs a diagnostic function by detecting a condition (pregnancy) or a marker for that condition (hCG).
No
The device description clearly states it is a "rapid lateral flow colloidal gold immunological test," which is a physical, hardware-based test strip, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "detection of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy." This involves testing a biological sample (urine) outside of the body to gain information about a physiological state (pregnancy).
- Device Description: The description details a "rapid lateral flow colloidal gold immunological tests for the qualitative determination of human chorionic gonadotropin (hCG) in urine or in urine and serum." This describes a test performed on biological samples (urine and serum) to determine the presence of a specific substance (hCG).
- Sample Type: The device uses urine and serum, which are biological specimens.
- Purpose: The purpose is to detect pregnancy, which is a medical condition or physiological state.
All of these characteristics align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
Accunate Home Pregnancy Test is an over-the-counter (OTC) one-step qualitative test for the detection of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy.
Product codes
LCX
Device Description
ACCUNATE ONE-STEP, ACCUNATE ONE-STEP CASSETTE and ACCUNATE-CHOICE are rapid lateral flow colloidal gold immunological tests for the qualitative determination of human chorionic gonadotropin (hCG) in urine or in urine and serum for the early detection of pregnancy.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Home User (ACCUNATE HOME PREGNANCY TEST); Professional User (ACCUNATE ONE-STEP CASSETTE)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Comparison studies were conducted at three clinic sites. Urine specimens from patients seeking confirmation of pregnancy were tested simultaneously with ACCUNATE ONE-STEP and ACCUNATE ONE-STEP CASSETTE and the Abbott Test Pack Plus™. A total of 131 specimens were tested. Test results showed 100% agreement with the Abbott Test Pack Plus™.
Serum specimens from normal male and non pregnant females were tested simultaneously with ACCUNATE-CHOICE™ and Quidel's Quick-Vue®. A total of 119 samples were tested. Test results showed 100% agreement with the Quick-Vue.
Twenty urine specimens and twenty serum specimens were spiked with hCG at concentrations of 5, 25, 50 and 100m IU/ml. Each urine specimen was tested at the hCG concentrations stated and at 0mlU/ml with ACCUNATE™ ONE-STEP, ACCUNATE™ ONE-STEP CASSETTES and ACCUNATE-CHOICE™. The serum specimens were tested with ACCUNATE-CHOICE™.
A study comparing the test results obtained by the home user with the ACCUNATE™ HOME PREGNANCY TEST to the test results obtained by the professional user with the ACCUNATE™ ONE-STEP CASSETTE was performed at three clinic sites. A total of 107 participants were included in this study.
Summary of Performance Studies
Comparison studies:
- Study Type: Comparison
- Sample Size: 131 urine specimens
- Key Results: 100% agreement with Abbott Test Pack Plus™ for ACCUNATE™-ONE STEP and ACCUNATE™-ONE STEP CASSETTE.
- Study Type: Comparison
- Sample Size: 119 serum specimens
- Key Results: 100% agreement with Quick-Vue® for ACCUNATE-CHOICE™.
Sensitivity Study:
- Study Type: Sensitivity
- Sample Size: 20 urine and 20 serum specimens per concentration (0, 5, 25, 50, 100 mIU/ml)
- Key Results: Sensitivity determined to be 25 mIU/ml.
Home User vs. Laboratory Professional Study:
- Study Type: Comparison
- Sample Size: 107 participants
- Key Results: 98% agreement between home user and laboratory professional test results for ACCUNATE™ HOME PREGNANCY TEST vs. ACCUNATE™ ONE-STEP CASSETTE.
Key Metrics
Sensitivity: 25mlU/ml
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
| Cenogenics Corporation | |
|---|---|
| 100 Route 520 • Drawer 308 | |
| Morganville, New Jersey 07751 | Telephone (732) 536-6457 • (800) 747-9457 |
| Fax (732) 972-8527 • e-mail: inquiry@cenogenics.com |
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
| Proprietary name: | ACCUNATE™-ONE STEP
ACCUNATE™ONE STEP CASSETTE
ACCUNATE-CHOICE™
ACCUNATE™ HOME PREGNANCY TEST |
|------------------------|-------------------------------------------------------------------------------------------------------|
| Common name: | Pregnancy test for urine or serum |
| Classification: | 21CFR862.1155, Class II |
| Classification number: | 75DHA |
| Establishment: | Cenogenics Corporation
100 Route 520
Morganville, New Jersey 07751 |
| Contact: | Nitza Katz
Vice President |
K030533
APR 17 2003
ACCUNATE™ONE-STEP, ACCUNATE™ONE-STEP CASSETTE and ACCUNATE-CHOICE™ are rapid lateral flow colloidal gold immunological tests for the qualitative determination of human chorionic gonadotropin (hCG) in urine or in urine and serum for the early detection of pregnancy.
Comparison studies were conducted at three clinic sites. Urine specimens from patients seeking confirmation of pregnancy were tested simultaneously with ACCUNATE™ONE-STEP and ACCUNATE™ONE-STEP CASSETTE and the Abbott Test Pack Plus™. The Test Pack Plus™ is a similar colloidal gold test for the qualitative determination of hCG in urine for the early detection of pregnancy. A total of 131 specimens were tested. Test results showed 100% agreement with the Abbott Test Pack Plus™. TABLE 1A demonstrates distribution of positive and negative specimens.
- Comparison of ACCUNATE™-ONE STEP and ACCUNATE™-ONE STEP 1A: TABLE CASSETTE with the Abbott Test Pack Plus™
| | ACCUNATE™-ONE STEP | ACCUNATE™-ONE STEP
CASSETTE | ABBOTT TEST PACK
PLUS™ |
|------------------|--------------------|--------------------------------|---------------------------|
| NO. OF POSITIVES | 63 | 63 | 63 |
| NO. OF NEGATIVES | 68 | 68 | 68 |
1
Serum specimens from normal male and non pregnant females were tested simultaneously with ACCUNATE-CHOICE™ and Quidel's Quick-Vue®. The Quick-Vue is a similar device for the qualitative determination of hCG in urine or serum for the early detection of pregnancy. A total of 119 samples were tested. Test results showed 100% agreement with the Quick-Vue . Table 1B shows the distribution of positive and negative samples.
TABLE 1B: Comparison of ACCUNATE-CHOICE™ with QUICK-VUE®
| ACCUNATE-CHOICE™ | QUICK-VUE® | |
|---|---|---|
| NO. OF POSITIVES | 59 | 59 |
| NO. OF NEGATIVES | 60 | 60 |
Twenty urine specimens and twenty serum specimens were spiked with hCG at concentrations of 5, 25, 50 and 100m IU/ml. Each urine specimen was tested at the hCG concentrations stated and at 0mlU/ml with ACCUNATE™ ONE-STEP, ACCUNATE™ ONE-STEP CASSETTES and ACCUNATE-CHOICE™. The serum specimens were tested with ACCUNATE-CHOICE™. Testing data demonstrates the sensitivity to be 25mlU/ml. Test results are shown in TABLE 2.
TABLE 2: Sensitivity Test Results
| hCG CONCENTRATION | |||||
|---|---|---|---|---|---|
| 0IU/ml | 5mlU/ml | 25mlU/ml | 50mlU/ml | 100mlU/ml | |
| NO. OF SAMPLES TESTED | 20 | 20 | 20 | 20 | 20 |
| POSITIVE RESULTS | 0 | 0 | 20 | 20 | 20 |
| NEGATIVE RESULTS | 20 | 20 | 0 | 0 | 0 |
A study comparing the test results obtained by the home user with the ACCUNATE™ HOME PREGNANCY TEST to the test results obtained by the professional user with the ACCUNATE™ ONE-STEP CASSETTE was performed at three clinic sites. A total of 107 participants were included in this study. The agreement between the home user and the laboratory professional test results was 98%. Table 3 shows the comparison test result data.
- TABLE 3: Comparison of the test results reported by the Home User with the test results reported by the laboratory.
| Home User | Laboratory | |
|---|---|---|
| Number of Positives | 47 | 46 |
| Number of Negatives | 59 | 61 |
| Number of Invalid | 1 | 0 |
| TOTAL | 107 | 107 |
2
The above testing data demonstrates that ACCUNATE™-ONE STEP and the ACCUNATE™-ONE STEP CASSETTE are substantially equivalent to the Abbott Test Pack Plus™ and that the ACCUNATE-CHOICE™ is substantially equivalent to Quidel's Quick-Vue°. The test results obtained by the home user with the ACCUNATE™ HOME PREGNANCY TEST is substantially equivalent to the test results obtained by the laboratory professional with the ACCUNATE™ ONE-STEP CASSETTE. The devices are equivalent in test principle, sensitivity and performance.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its wings and body. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
APR 1 7 2003
Ms. Nitza Katz Vice President Cenogenics. Corporation 100 Route 520 Morganville, NJ 07751
K030533 Trade/Device Name: Accunate Home Pregnancy Test Regulation Number: 21 CFR 862.1155 Regulation Name: Human Chorionic Gonadotropin (HCG) Test System Regulatory Class: Class II Product Code: LCX Dated: February 10, 2003 Received: February 14, 2003
Dear Ms. Katz:
Re:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
4
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97), Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Page
of
510(k) Number (if known): K030533
Device Name: ACCUNATE HOME PREGNANCY TEST
Indications For Use:
Accunate Home Pregnancy Test is an over-the-counter (OTC) one-step qualitative test for the detection of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Carol C Benson/P Jean Cooper
(Division Sign-Off) Division of Clinical Laborator 510(k) Number
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter
(Optional Format 1-2-96)